ModifiedPremera BluecrossPolicy N/A

Pharmacologic Treatment of Sleep Disorders (drug-specific coverage)

This pharmacy policy defines medical necessity criteria, dosing limits, prior therapy requirements, and documentation for pharmacologic treatments of narcolepsy, cataplexy, idiopathic hypersomnia, obstructive sleep apnea, and shift work disorder for Premera Bluecross members.

Policy Summary

PayerPremera Bluecross

PolicyPharmacologic Treatment of Sleep Disorders (drug-specific coverage)

Policy CodePolicy N/A

Change TypeAge requirement updatesproduct additions and clarifications

Effective Date1, 2025

Next Review DateN/A

Key ActionPrior therapy with stimulants and modafinil/armodafinil must be ineffective, not tolerated, or contraindicated before coverage of alternative listed agents.

SourceLink

POLICY UPDATE CHANGES

Updated Wakix (pitolisant) coverage criteria age requirement from adults to 6 years or older for the treatment of excessive daytime sleepiness (EDS) with narcolepsy.

Added coverage criteria for Lumryz (sodium oxybate) for treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy; Lumryz is an extended-release formulation taken once at bedtime.

Clarified that Xyrem, Sunosi, and Wakix are not to be used in combination with each other as efficacy and safety have not been evaluated.

Updated multiple age requirements (Lumryz, brand sodium oxybate, Xywav, Sunosi, Wakix) for cataplexy and EDS coverage; several products' minimum ages were lowered to 6 or 7 years as specified.

Added coverage for Nuvigil (armodafinil) and Provigil (modafinil) to improve wakefulness for narcolepsy, OSA, or shift work disorder.

9 g/daymax dose sodium oxybate

150 mg/daymax dose Sunosi

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Drug-Specific Coverage Criteria

Lumryz (sodium oxybate) — Cataplexy and Excessive Daytime Sleepiness in Narcolepsy

Covered when ALL of the following are met

Age: Individual is aged 7 years or older

Cataplexy documentation (for cataplexy indication): Cataplexy documented by brief episodes of sudden bilateral loss of muscle tone with maintained consciousness that are precipitated by an emotional trigger such as laughter or joking

Narcolepsy diagnosis (for EDS indication): Diagnosis documented by sleep study: Nocturnal PSG showing REM sleep latency <= 15 minutes OR MSLT showing mean sleep latency <= 8 minutes and >= 2 sleep-onset REM periodsPSG REM latency <= 15 min; MSLT mean <= 8 min and >=2 SOREMPs

Prior therapy with brand sodium oxybate (Xyrem) was ineffective, not tolerated, or contraindicated

Also requires prior stimulants and modafinil/armodafinil failure for EDS indication per product-specific criteria

Dose limit: Dose prescribed is limited to 9 grams per day<=9 g/day

Combination therapy restriction: Not used in combination with Sunosi (solriamfetol), Wakix (pitolisant), brand sodium oxybate (Xyrem), or Xywav

Brand sodium oxybate / Xyrem — Cataplexy and EDS in Narcolepsy

Covered when ALL of the following are met

Age: Individual is aged 7 years or older

Cataplexy documentation: Cataplexy documented by either typical cataplexy description OR in children/within 6 months of onset spontaneous grimaces/jaw-opening with tongue thrusting or global hypotonia

Prior therapy with a stimulant (e.g., methylphenidate) and with modafinil (Provigil) or armodafinil (Nuvigil) was ineffective, not tolerated, or contraindicated

Dose limit: Dose prescribed is limited to 9 grams per day<=9 g/day

Nuvigil (armodafinil) and Provigil (modafinil)

Covered when ALL of the following are met

Age: Individual is aged 18 years or older

Prior therapy: Has tried generic armodafinil/modafinil first and had inadequate response or intolerance

Dose limits: Nuvigil (armodafinil) limited to 250 mg/day for narcolepsy or OSA; Provigil (modafinil) limited to 200 mg/day<=250 mg/day (armodafinil); <=200 mg/day (modafinil)

SWD dosing limits differ (armodafinil 150 mg/day)

Sunosi (solriamfetol) — Excessive Daytime Sleepiness

Covered when ALL of the following are met

Age: Individual is aged 18 years or older

EDS documentation: Excessive daytime sleepiness documented by recurrent periods within the same day of an irrepressible need to sleep, lapsing into sleep, or napping, occurring at least 3 times per week for at least 3 months

Diagnosis documentation: Narcolepsy documented by PSG REM latency <=15 min OR MSLT mean <=8 min AND >=2 SOREMPs; OR OSA documented by AHI criteria (>=15 events/hr or 5-14 with qualifying risk factors and minimum event counts)PSG REM latency <=15 min; MSLT mean <=8 min and >=2 SOREMPs; AHI >=15 or 5-14 with risk factors

Prior therapy with a stimulant (e.g., methylphenidate) and with modafinil (Provigil) or armodafinil (Nuvigil) was ineffective, not tolerated, or contraindicated

Wakix (pitolisant)

Covered when ALL of the following are met

Age for cataplexy: Individual is aged 18 years or older for the cataplexy indication

Age for EDS: Individual is aged 6 years or older for the EDS indicationage >= 6 years

Cataplexy documentation: Cataplexy documented by typical description OR pediatric presentations (spontaneous grimaces or jaw-opening with tongue thrusting or global hypotonia) within 6 months of onset

Hepatic impairment exclusion: Individual does not have severe hepatic impairment (Child-Pugh C) as documented by laboratory tests

Xywav (calcium, magnesium, potassium, and sodium oxybates)

Covered when ALL of the following are met

Age: Individual is aged 7 years or older for narcolepsy indications

Cataplexy documentation: Cataplexy documented by typical description OR in children/within 6 months of onset spontaneous grimaces/jaw-opening with tongue thrusting or global hypotonia

Exception may be granted if individual has concomitant heart failure, hypertension, or renal impairment

Prior therapy with brand sodium oxybate (Xyrem) was ineffective, not tolerated, or contraindicated

Exception noted for certain comorbidities

Dose limit: Dose prescribed is limited to 9 grams per day<=9 g/day

Xywav for Idiopathic Hypersomnia

Covered when ALL of the following are met

Age: Individual is aged 18 years or older

Diagnostic criteria: Daily irrepressible need to sleep or daytime lapses into sleep for at least 3 months; absence of cataplexy; no other identifiable cause; confirmation by MSLT (mean <=8 minutes and <2 SOREMPs) OR 24-hour PSG total sleep time >= 660 minutesMSLT mean <=8 min and <2 SOREMPs OR 24-hour total sleep time >=660 minutes

Prior therapy with a stimulant (e.g., methylphenidate) and with modafinil (Provigil) or armodafinil (Nuvigil) was ineffective, not tolerated, or contraindicated

Combination therapy restriction: Xywav not used in combination with Lumryz, Sunosi, Wakix, or brand sodium oxybate (Xyrem)

Product-specific coverage summaries (excerpt)

Policy coverage is handled per specific product criteria; notable criteria changes recorded here.

Wakix (pitolisant) EDS in narcolepsy: Coverage requires meeting product-specific criteria; age requirement updated to 6 years or older.age >= 6 years

See full policy for diagnostic and prior therapy requirements

Lumryz (sodium oxybate) for cataplexy or EDS: Coverage requires meeting product-specific criteria; age requirement updated to 7 years or older for cataplexy and EDS.age >= 7 years

Lumryz is an extended-release formulation taken once at bedtime.

Xyrem/brand sodium oxybate and Xywav: Coverage criteria updated to include minimum age requirements (many to 7 years or older) and clarifications about concurrent use with Lumryz; these products must follow FDA dosing and administration.

All uses of the medications listed in this policy that are not specifically described under the product-specific coverage criteria are considered investigational. This includes any indication, dosing, or combination not outlined in the policy.

The FDA reviewed trials of sodium oxybate for fibromyalgia and rejected approval in 2010 due to concerns regarding potential for abuse and diversion; the trials were placebo-controlled and the FDA panel concluded the risk of abuse outweighed any demonstrated benefit.

Requests for concurrent use of sodium oxybate products (including Xyrem) with other wake-promoting agents listed in this policy such as Sunosi (solriamfetol) or Wakix (pitolisant) are not allowed because the efficacy and safety of these combinations have not been evaluated. The policy explicitly prohibits combination use of Xyrem, Sunosi, and Wakix.

Dose limits are set to align with available clinical evidence and FDA prescribing information. For all sodium oxybate products (brand Xyrem, Xywav, Lumryz), doses > 9 g/day are not supported by clinical evidence and are considered not medically necessary. For wakefulness agents, modafinil (Provigil) doses > 200 mg/day and armodafinil (Nuvigil) doses > 250 mg/day for narcolepsy/OSA (and >150 mg/day for SWD with armodafinil) are considered not medically necessary; Sunosi doses >150 mg/day and Wakix doses >35.6 mg/day are also not supported.

An unpublished meta-analysis of six randomized trials in individuals with obstructive sleep apnea and excessive daytime sleepiness reported no clinically meaningful difference in Epworth Sleepiness Scale outcomes between Sunosi 150 mg daily and modafinil 200 mg daily; limitations and incomplete reporting (for example MWT results for modafinil) were noted.

Diagnostic Thresholds and Measurements

inv-14: MSLT mean sleep latency — diagnostic threshold for narcolepsy

ThresholdMSLT mean sleep latency ≤ 8 minutes

ContextUsed to support a narcolepsy diagnosis for excessive daytime sleepiness when documented on MSLT

Associated requirementMSLT mean ≤8 min typically accompanied by ≥2 SOREMPs for narcolepsy criteria

inv-15: PSG REM latency — diagnostic criterion for narcolepsy

ThresholdPolysomnography (PSG) REM sleep latency ≤ 15 minutes

ContextPSG REM latency ≤15 min may be used as part of sleep-study documentation for narcolepsy diagnosis

Prior Authorization, Documentation, and Step Therapy

Prior Authorization

Prior Therapy Required

Prior therapy requirements — trials of listed agents are required prior to approval. For modafinil/armodafinil, the member must have tried the generic form (generic modafinil or generic armodafinil) and had inadequate response or intolerance prior to approving brand Provigil (modafinil) or Nuvigil (armodafinil). For Sunosi (solriamfetol), prior therapy with a stimulant (e.g., methylphenidate) and prior trial of modafinil or armodafinil that were ineffective, not tolerated, or contraindicated is required. For Lumryz, Xyrem, and Xywav, prior therapy with brand sodium oxybate or Xyrem must be ineffective, not tolerated, or contraindicated when listed in the coverage criteria.

Modafinil/Armodafinil: try generic first; documented inadequate response or intolerance required
Sunosi: trial of stimulant (eg, methylphenidate) AND trial of modafinil or armodafinil required unless contraindicated
Sodium oxybate products (Lumryz/Xyrem/Xywav): prior therapy with brand sodium oxybate or Xyrem required unless ineffective/intolerable/contraindicated

Clinical Background and Context

Excessive daytime sleepiness (EDS) is a common symptom of disorders such as narcolepsy and obstructive sleep apnea and should prompt diagnostic evaluation prior to chronic pharmacologic therapy. Proper evaluation includes a clinical history documenting persistent inability to stay awake and alert for at least three months, and when indicated objective sleep testing (for example polysomnography and multiple sleep latency testing) to confirm narcolepsy or other sleep disorders. The policy notes that pharmacologic agents are adjunctive treatments when diagnostic and prior-therapy criteria are met.

Key Definitions

inv-31: Cataplexy definition (brief episodes of bilateral loss of muscle tone)

DefinitionBrief episodes of sudden bilateral loss of muscle tone with maintained consciousness precipitated by an emotional trigger (e.g., laughter or joking)

Pediatric/early onset noteIn children or early onset, cataplexy may present with spontaneous grimaces, jaw‑opening with tongue thrusting, or global hypotonia without obvious emotional triggers

Documentation useCataplexy documentation is required for product coverage for cataplexy indications (e.g., Lumryz, Xywav) and must be recorded in medical records

inv-32: Idiopathic hypersomnia definition

DefinitionDaily irrepressible need to sleep or daytime lapses into sleep for at least 3 months in the absence of cataplexy and other identifiable causes

Confirmation

Policy Changes and Material Updates

2025-07-01annual_reviewLatest

Annual review approved June 10, 2025: clarified non-formulary exception authorizations may be approved up to 12 months and reaffirmed adherence to FDA dosing and administration; updated multiple product age requirements including Lumryz, brand sodium oxybate/Xyrem, Xywav, Sunosi, and Wakix.

2024-09-01policy_update

Annual review approved August 13, 2024: reviewed prescribing information and updated Wakix age requirement from adults to 6 years or older for EDS with narcolepsy.

2024-01-01

Policy Summary

PayerPremera Bluecross

PolicyPharmacologic Treatment of Sleep Disorders (drug-specific coverage)

Policy CodePolicy N/A

Change TypeAge requirement updatesproduct additions and clarifications

Effective Date1, 2025

Next Review DateN/A

Key ActionPrior therapy with stimulants and modafinil/armodafinil must be ineffective, not tolerated, or contraindicated before coverage of alternative listed agents.

SourceLink

On This Page

Billing Rule

Pharmacy Benefit & Restricted Distribution

Pharmacy benefit management and restricted distribution: this policy is managed through the pharmacy benefit and certain products (e.g., Xyrem) are available only through a single-pharmacy limited distribution program (Xyrem Success Program); prescribers and patients must be registered in the program to obtain product.

Policy managed via pharmacy benefit
Xyrem: single-pharmacy limited distribution (Xyrem Success Program) — prescriber and patient registration required

Note

Authorization Duration & FDA Dosing

Authorization duration and adherence to FDA labeling — non-formulary exception reviews and other authorizations for listed drugs may be approved up to 12 months when criteria are met; dosing must adhere to the product's FDA-approved dosage and administration.

Non-formulary exception and other approvals may be authorized up to 12 months when criteria are met
Medications subject to the product's FDA dosage and administration prescribing information

Documentation Required

Documentation Required for Review

Required documentation for review — medical records submitted must document that all medical necessity criteria are met. Missing required documentation may result in denial.

Office visit notes with relevant history, diagnosis, and medication history must be provided
Documented sleep study results when required (e.g., MSLT, PSG) must be included
For initial and re-authorization reviews, include documentation of continued clinical response when required

Denial Risk

Dose Limits — Denial Risk

Dose limits trigger denial risk — doses greater than product maximums are not supported by clinical evidence and may be denied. Examples include sodium oxybate products (Lumryz, Xyrem, Xywav) limited to 9 grams per day; Nuvigil and Provigil dose limits (Nuvigil ≤250 mg/day for narcolepsy/OSA; Provigil ≤200 mg/day); Sunosi limited to 150 mg once daily; Wakix limited to 35.6 mg once daily.

Sodium oxybate products: doses >9 g/day considered not medically necessary
Nuvigil: doses >250 mg/day for narcolepsy/OSA (and >150 mg/day for SWD) not supported
Provigil: doses >200 mg/day not supported
Sunosi: limit 150 mg once daily
Wakix: limit 35.6 mg once daily

Denial Risk

Combination Therapy Not Allowed

Combination therapy prohibition — requests for concurrent use of listed sodium oxybate products and certain wake-promoting agents may be denied. Lumryz, brand sodium oxybate/Xyrem, Xywav, Sunosi (solriamfetol), and Wakix (pitolisant) are not to be used in combination with each other; combination use has not been evaluated for efficacy and safety.

Do not combine Lumryz, Xyrem/brand sodium oxybate, or Xywav with Sunosi, Wakix, or each other
Combination use may be denied due to lack of evidence on safety/efficacy

Note

Verify Member Benefit & Limits

Benefit verification — confirm member benefit plan limits and applicable coverage before submitting a request. Consult the member benefit booklet or contact customer service to determine whether there are any benefit limitations applicable to the requested service or supply.

Verify member-specific pharmacy benefit coverage prior to authorization
Contact customer service or review member booklet for benefit limits and exclusions

Step Therapy

Step Therapy & Re-Authorization (Excerpt)

Step therapy (excerpt) — non-formulary exception and other reviews may be approved up to 12 months when drug-specific criteria are met and chart notes show continued clinical response. Available alternative stimulants and step options (e.g., trial of methylphenidate, generic modafinil/armodafinil) should be documented when required.

Document trials of alternative stimulants (eg, methylphenidate) when required for Sunosi
Document trial and failure/intolerance of generic modafinil/armodafinil before approving branded agents
Re-authorization: provide documentation of continued clinical response for approvals up to 12 months

inv-35: Cataplexy (alternate entry) — child-focused description

DescriptionIn children, cataplexy may present as brief episodes of bilateral loss of muscle tone with maintained consciousness precipitated by emotion, or as spontaneous grimaces, jaw‑opening with tongue thrusting, or global hypotonia without obvious emotional triggers

Age considerationsPediatric presentations are specifically noted in coverage criteria for oxybate products (e.g., Xywav, Lumryz) and may alter documentation expectations

DocumentationPediatric cataplexy descriptions may be accepted in lieu of typical adult emotional‑trigger descriptions when recorded in medical records